As VEGF-B is able to induce ceramide accumulation and mitochondrial dysfunction in the heart due to the imbalance of fatty acid uptake and oxidation [42], the therapeutic use of VEGF-B to treat heart failure in diabetes or dyslipidemia could also have disadvantages. Here, VEGFB is linked to metabolic syndrome.